What is the purpose of this trial?
The purpose of this study is to determine which combination of Nivolumab plus either Rucaparib, Docetaxel, or Enzalutamide is the most effective in treating Castration-resistant Prostate Cancer that has spread
Bristol-Myers Squibb Research and Development
Start Date: 09/27/2018
End Date: 02/18/2020
Last Updated: 12/04/2018
Study HIC#: 2000022918